Thanks to the development of technology, the presence of electric vehicles (EVs) on the roads is no longer a purely theoretical issue. Also in Poland, electric cars are already visible on the streets, and charging stations (EVCS) are increasingly being installed near newly emerging buildings and housing estates. The article attempts to determine to what extent the use of electric cars will affect the demand for power and energy in the Polish electric power system (PEPS). The basis for PEPS modernization plans should be a detailed analysis of the technical adequacy of all its subsystems: generation, transmission and distribution, on the basis of which it will be possible to assess the potential impact of EVCS infrastructure operation on the Polish electric power system. This publication presents an example of such analysis for the distribution sub- sector, most exposed to potential negative interactions with the future, extensive infrastructure of EVCS.
Electric buses are increasingly appearing on the streets of cities around the world. Thus, it is necessary to consider the impact of their charging on the distribution system operation, especially near the charging point. This article presents the problems that may arise while new charging points are connected. Research was carried out on the existing charging point at Spartańska Street in Warsaw, which allowed to obtain daily bus charging profiles and voltage curves. The authors then proposed an exemplary model of a bus terminus with the designed infrastructure for charging buses, based on the assumptions of the public transport operator in Warsaw. The comparison of these two solutions was made and based on it, a methodology of calculating daily demand for any terminus was prepared. In addition, no problems with the power quality were found during the research. This allows us to state that the introduction of electric buses into the fleet of passenger carriers will have a minor impact on the operation of the power system in Warsaw.
Aim of the study. The 4C Mortality Score was created to predict mortality in hospitalised patients with COVID-19 and has to date been evaluated only in respiratory system disorders. The aim of this study was to investigate its application in patients with COVID-19-associated acute ischaemic stroke (AIS).Clinical rationale for study. COVID-19 is a risk factor for AIS. COVID-19-associated AIS results in higher mortality and worse functional outcome. Predictors of functional outcome in COVID-19-associated AIS are required.
Materials and methods.This was a retrospective observational study of patients with AIS hospitalised in seven neurological wards in Małopolska Voivodship (Poland) between August and December 2020. We gathered data concerning the patients' age, sex, presence of cardiovascular risk factors, type of treatment received, and the presence of stroke-associated infections (including pneumonia, urinary tract infection and infection of unknown source). We calculated 4C Mortality Score at stroke onset, and investigated whether there was a correlation with neurological deficit measured using the National Health Institute Stroke Scale (NIHSS) and functional outcome assessed using the modified Rankin Scale (mRS) at discharge.
Results.The study included 52 patients with COVID-19-associated AIS. The 4C Mortality Score at stroke onset correlated with mRS (r s = 0.565, p < 0.01) at discharge. There was also a statistically significant difference in the mean 4C Mortality Score between patients who died and patients who survived the stroke (13.08 ± 2.71 vs. 9.85 ± 3.47, p = 0.04).Conclusions and clinical implications. 4C Mortality Score predicts functional outcome at discharge in COVID-19-associated AIS patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.